Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +75

Alteogen Enters into a License Agreement with Biogen for Development ...

🤝 Alteogen Inc. and Biogen Inc. have entered an exclusive license agreement for the development and commercialization of subcutaneous formulations using ALT-B4 technology.

💊 The deal covers two biologic products that will be converted from intravenous infusion to more convenient subcutaneous administration via Alteogen's Hybrozyme™ platform.

💰 Alteogen will receive an upfront payment of US$20 million as part of the agreement terms.

💵 The company is eligible for an additional US$10 million upon initiating development of the second product under the contract.

🚀 Long-term payments can total up to US$549 million in combined development, regulatory, and sales milestone payments for both products.

📈 Following commercialization, Alteogen will receive ongoing royalties based on net sales of the partnered therapeutics.

👣 Biogen retains an option to develop a third product beyond the initial two agreed upon under the license terms.

⚗️ ALT-B4 (berahyaluronidase alfa) is a proprietary recombinant human hyaluronidase designed to facilitate rapid drug absorption through subcutaneous routes.

🩸 The technology works by temporarily depolymerizing hyaluronan in the extracellular matrix to allow large-volume drug dispersion.

🌏 Tae-Yon Chun, CEO of Alteogen, expressed strong enthusiasm for partnering with Biogen to advance innovative therapies together.

🎓 Vivek Shenoy serves as Chief Business Officer at Alteogen and can be reached via phone or email for business inquiries.

🇰🇷 Alteogen is a South Korea-based biopharmaceutical company listed on the KOSDAQ exchange with the ticker symbol 196170.

💊 The company focuses on novel biologics including antibody-drug conjugates, biobetters, biosimilars, and long-acting therapeutic proteins.

🧬 Alteogen utilizes proprietary NexP™-fusion and NexMab™ platform technologies alongside its Hybrozyme™ technology for drug development.

📅 The news release regarding this partnership was distributed via PRNewswire on March 25, 2026.

Bullish Signals
  • Alteogen has secured an exclusive license agreement with global biotechnology leader Biogen Inc. for the development and commercialization of two subcutaneous formulations utilizing its ALT-B4 technology.
  • The company will receive a significant upfront payment of US$20 million immediately upon signing the deal.
  • Alteogen is eligible to receive an additional US$10 million contingent on the initiation of development for the second product under the agreement.
  • The total potential value of this partnership is substantial, with eligibility for up to US$549 million in combined development, regulatory, and sales milestone payments following commercialization.
  • Beyond the initial two products, Biogen holds an option to develop a third product utilizing the same advanced technology platform.
  • Alteogen will generate ongoing revenue streams through royalties based on net sales once the products reach the market.
  • This partnership validates Alteogen's Hybrozyme™ technology and its proprietary recombinant human hyaluronidase (ALT-B4), which enables the conversion of IV biologics to more convenient subcutaneous formulations.
Risk Factors
  • The agreement is exclusively with Biogen, a competitor in many areas of the biologics space, meaning Alteogen may not benefit from similar licensing deals with other major pharma giants.
Full Analysis
Biogen Inc. has entered into an exclusive license agreement with Alteogen Inc., a South Korean biopharmaceutical company, to develop and commercialize subcutaneous (SC) formulations of two biologics that utilize Alteogen's ALT-B4 technology. The deal involves ALT-B4, a proprietary recombinant human hyaluronidase enzyme developed using Alteogen's Hybrozyme™ platform, which is designed to convert drugs typically administered via intravenous infusion into more convenient subcutaneous forms by temporarily depolymerizing hyaluronan in the extracellular matrix. Under the terms of the agreement, Biogen will receive exclusive rights for two specific biologic products and retains an option to develop a third product. Alteogen is set to receive an upfront payment of US$20 million and may become eligible for an additional US$10 million contingent upon the initiation of development for the second product. Furthermore, the agreement stipulates that Alteogen could earn up to US$549 million in milestone payments covering development, regulatory approval, and sales phases, alongside royalty rights based on future net sales once commercialization begins. Alteogen, listed on the KOSDAQ (ticker: 196170), focuses on novel biologics including antibody-drug conjugates (ADCs) and biobetters using its NexP™-fusion and NexMab™ platform technologies. This partnership highlights the strategic shift toward subcutaneous delivery methods for large molecules, aiming to improve patient compliance through easier administration compared to IV infusions. The collaboration underscores Biogen's commitment to advancing innovative therapies while providing Alteogen with significant financial milestones tied to the successful development and market adoption of these new formulations.